

Monoclonal Anti-Influenza A Virus H7 Hemagglutinin (HA), A/Shanghai/1/2013 (H7N9) Clone 1H5 (produced *in vitro*)

Catalog No. NR-51193

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Florian Krammer, Ph.D., Departments of Medicine and Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA, provided under government contract by NIAID/CEIRS

Manufacturer:

BEI Resources

Product Description:

Antibody Class: IgG2a

Mouse monoclonal antibody prepared against hemagglutinin from influenza virus, A/Shanghai/1/2013 (H7N9) was purified from hybridoma supernatant by protein G affinity chromatography. The B cell hybridoma was generated by the fusion of Sp2/0 myeloma cells with splenocytes from BALB/c mice electroporated in the calf muscle with a plasmid expressing hemagglutinin from influenza virus, A/Shanghai/1/2013 (H7N9).^{1,2}

Material Provided:

Each vial of NR-51193 contains approximately 100 µL of purified monoclonal antibody in PBS. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-51193 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-51193 is specific to the H7 HA of influenza virus as determined by ELISA.²

Applications: Western blot analysis, immunofluorescence, ELISA, hemagglutination inhibition, flow cytometry and neutralization.^{1,2}

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Influenza A Virus H7 Hemagglutinin (HA), A/Shanghai/1/2013 (H7N9) Clone 1H5 (produced *in vitro*), NR-51193.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services,

Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Krammer, F., Personal Communication.
2. Tan, G. S., et al. “Broadly-Reactive Neutralizing and Non-Neutralizing Antibodies Directed Against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.” PLoS Pathog. 12 (2016): e1005578. PubMed: 27081859.

ATCC® is a trademark of the American Type Culture Collection.

